<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	.scrollable{
        width:915px;
        height:415px;
        overflow-y: auto;
    }

    .scrollable ul{
        margin-left:20px;
        margin-top:95px;
    }

    .scrollable li{
        list-style-type: decimal;
        list-style-position: inside;
        font-size:16px;
        text-indent: -20px;
        font-family:interstatebold;
    }

    .scrollable li > span{
        font-family:interstateregular;
        display: inline;
    }

</style> 
</head>
<body>
	<section id="container" data-slide="home">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
            <span class='logo lymp'></span>
            <h3>REFERENCES</h3>
            <div class='scrollable'>
                <ul>
                    <li>
                        <span>Weil, MK. and Chen, M.D. 2011. PARP inhibitor treatment in ovarian and breast cancer. Curr Prob Cancer. 35(1), pp.7–50.</span>
                    </li>
                    <li>
                        <span>Ledermann, J. et al. 2012. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 366 (15), pp.1382-1392.</span>
                    </li>
                    <li>
                        <span>Ledermann, J. et al. 2014. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 15(8), pp.852-856.</span>
                    </li>
                    <li>
                        <span>Lynparza (olaparib) Approved Product Information. 7 January 2016</span>
                    </li>
                    <li>
                        <span>Goff, B.A. et al. 2000. Ovarian carcinoma diagnosis. Cancer. 89(10), pp.2068-75.</span>
                    </li>
                    <li>
                        <span>Ledermann, J. and Raja, F.A. et al. 2013. Newly diagnosed and relapsed epithelia ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(6), pp.24-32.</span>
                    </li>
                    <li>
                        <span>Caldecott, K.W. 2003. Protein–proteins interactions during mammalian DNA singlestrand break repair. Biochem Soc Trans. 31 (Pt 1), pp.247-251.</span>
                    </li>
                    <li>
                        <span>Langelier, M.F. et al. 2014. PARP-2 and PARP-3 are selectively activated by 5 phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res. 42(12), pp.7762-7775.</span>
                    </li>
                    <li>
                        <span>Hegde, M.L. et al. 2008. Early Steps in the DNA Base Excision/Single-Strand Interruption Repair Pathway in Mammalian Cells. Cell Res. 18(1), pp.27–47.</span>
                    </li>
                    <li>
                        <span>Amal, A. and Ganesan. S. 2011. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. Journal of Molecular Cell Biology. 3, pp. 66-74.</span>
                    </li>
                    <li>
                        <span>Weston, V.J. and Oldreive, CE. et al. 2010. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 116(22), pp. 4578-4587.</span>
                    </li>
                    <li>
                        <span>Matulonis UA et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016 Apr 8. doi: 10.1002/cncr.29995. [Epub ahead of print]</span>
                    </li>
                    <li>
                        <span>Aslop, K. et al. 2012.BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol. (30)21, pp.2655-2663.</span>
                    </li>
                    <li>
                        <span>Stavropoulo, A.V. et al. 2013. Prevalence of BRCA1 mutations in familial and sporadic Greek ovarian cancer cases. PLOS One. 8(3), pp.1-10.</span>
                    </li>
                    <li>    
                        <span>Pal, T. et al. 2005. BRCA1 and BRCA2 Mutations. Account for a Large Proportion of Ovarian Carcinoma Cases. Cancer. 104(12), pp.2807-2816.</span>
                    </li>
                    <li>
                        <span>Song, H. et al. 2014. The contribution of deleterious germline mutations in BRCA1,BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 23(17), pp.4703-4709.</span>
                    </li>
                    <li>
                        <span>Kurian, A.W. 2010. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr Opin Obstet Gynecol. 22(1), pp.72-78.</span>
                    </li>
                    <li>
                        <span>Society of Gynecologic Oncology. [Online]. [Accessed 12 March 2015]. Available from: https://www.sgo.org/clinical-<br />practiceguidelines/genetic-testing-for-ovariancancer/.
                    </li>
                </ul>
            </div>
            
        </article>
    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		$(".btn").on('tap', function(){
            var popup = $(this).siblings('p');
            $(popup).is(':visible') ? $().ad.fadeOut() : $(popup, this).fadeIn();
        })
		
	})

</script>
</body>
</html>
